4386-39-4

Usage

Uses

Used in Pain Relief and Fever Reduction:
Aspirin is used as an analgesic and antipyretic agent for the relief of mild to moderate pain and reduction of fever. Its mechanism of action involves the inhibition of prostaglandin synthesis, which are chemicals responsible for pain, inflammation, and fever.
Used in Anti-Inflammatory Applications:
Aspirin is used as an anti-inflammatory agent, helping to reduce inflammation in various conditions such as arthritis, tendinitis, and bursitis. By inhibiting the production of prostaglandins, it alleviates the symptoms of inflammation, including swelling, redness, and heat.
Used in Cardiovascular Health:
Aspirin is used as an antiplatelet and anticoagulant agent, making it effective in preventing heart attacks and strokes. Its ability to inhibit platelet aggregation and reduce blood clot formation helps to maintain proper blood flow and prevent the formation of clots that can lead to cardiovascular events.
Used in Over-the-Counter Medications:
Aspirin is available over-the-counter in various forms such as tablets, chewable tablets, and effervescent tablets, making it easily accessible for individuals seeking relief from pain, fever, and inflammation.

InChI:InChI=1/C10H10O4/c1-6-4-3-5-8(10(12)13)9(6)14-7(2)11/h3-5H,1-2H3,(H,12,13)

Upstream product

• 83-40-9 3-methylsalicylic acid 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 1261297-83-9 (S)-2-(2-(1-hydroxy-3-phenylprop-2-yl)-2-isopropylhydrazinecarbonyl)-6-methylphenyl acetate 
• 1375074-76-2 4-imino-9-methyl-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-5H-chromeno[2,3-d]pyrimidine-5-one 
• 1237514-77-0 2-(2-hydroxy-3-methylbenzamido)-4-phenylbenzoic acid 
• 1237519-27-5 methyl 2-(2-acetoxy-3-methylbenzamido)-4-phenylbenzoate 
• 1221683-30-2 (2-hydroxy-3-methylbenzoyl)-N-(4-phenylthiazol-2-yl)amine 
• 1092448-12-8 2-(2-acetoxy-3-methyl-benzoyl-amino)-indane-2-carboxylic acid ethyl ester 
• 53658-16-5 N-benzyl-3-methylsalicylamide 
• 93610-16-3 2-hydroxy-3-hydroxymethyl-benzoic acid 
• 115978-94-4 (Z)-1,3,3-trimethyl-2-(2-hydroxy-3-methylphenacylidene)indoline 
• 115978-93-3 (E)-1,3,3-trimethyl-2-(2-hydroxy-3-methylphenacylidene)indoline 
• 99601-61-3 C₂₂H₃₆NO₃P 

Relevant academic research and scientific papers

Structural Studies on Chemical Models of Enzymatic Catalysis: 2-Acetoxy-3-methylbenzoic Acid

C10H10O4, monoclinic, P21/c, a=4.910 (1), b=11.702 (2), c=17.233 (6) Angstroem, β=98.36 (2) deg, Z=4, dc=1.317 (1) Mg m-3, R=0.032 for 615 observed data measured by diffractometer.The carboxyl group is twisted by 11.9 (6) deg out of the plane of the aromatic ring, and the acetoxy group is also twisted out of plane by 85.5 (5) deg.The ester oxygen atom O(3) lies out of plane of the aromatic ring by 0.17 (1) Angstroem.The carboxyl group is oriented such that its shorter C-O bond is syn to the acetoxy group, unlike aspirin in which it is anti.The molecule forms dimers with linear, asymmetric hydrogen bonds having O...O 2.627 (3) Angstroem.

Development of methylated cobalt–alkyne complexes with selective cytotoxicity against COX-positive cancer cell lines

Derivatives of the cytotoxic cyclooxygenase (COX) inhibitor [(prop-2-ynyl)?2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS) with a methyl group in the 3, 4, 5, or 6 position of the acetylsalicylic acid (ASS) scaffold were synthesized with the aim to achieve enhanced selectivity for COX-2. From this modification, a higher specificity for COX-2-expressing tumors is expected, preventing COX-1-mediated side effects. The cobalt–alkyne complexes were tested for their COX-inhibitory and antiproliferative properties as well as their cellular uptake. Methylation reduced the effects at the isolated COX-1, whereas those at the isolated COX-2 remained nearly constant compared to Co-ASS. In cellular systems, the new compounds showed superior cytotoxicity toward the COX-positive HT-29 colon carcinoma cells than cisplatin. The reduced growth-inhibitory potency in T-24 cells, which express distinctly fewer COX enzymes (COX-1/COX-2 = 50/1) than HT-29 cells (COX-1/COX-2 = 50/50), and the only marginal activity in COX-negative MCF-7 breast cancer cells point to an interference in the arachidonic acid cascade through COX-2 inhibition as part of the mode of action, especially as the cellular uptake was even higher in MCF-7 cells than in T-24 cells. These findings clearly demonstrate that the methylated cobalt–alkyne complexes possess promising potential for further development as reasonable alternatives to the limited platinum-based antitumor agents.

Synthesis method of 1-hydroxy-2,5,8-trimethyl-9-fluorenone

The invention belongs to the field of natural medicine synthesis, and discloses a method for synthesizing1-hydroxy-2,5,8-trimethyl-9-fluorenone, wherein 3-methylsalicylic acid and p-xylene are used asraw materials, 3-methylsalicylic acid is firstly acylated with acetyl chloride to prepare 3-methylacetylsalicylic acid, and the3-methylacetylsalicylic reacts with p-xylene by taking palladium acetateas a catalyst, sodium persulfate as an oxidizing agent, N-acetyl-L-isoleucine, dimethyl sulfoxide and trifluoromethanesulfonic acid as complexing agents to synthesize the 1-hydroxy-2,5,8-trimethyl-9-fluorenone.

Synthesis and application of oxadiazines as chiral ligands for the enantioselective addition of diethylzinc to aldehydes

A series of oxadiazines derived from l-phenylalanine bearing phenolic substituents have been synthesized in a multistep, one pot process. This process involves the reaction of a mixed anhydride with a β-hydrazino alcohol, methanesulfonylation of the alcohol moiety, and base induced cyclization. The resultant oxadiazines were employed in the asymmetric addition of diethylzinc to aldehydes.

Amide-containing diketoacids as HIV-1 integrase inhibitors: Synthesis, structure-activity relationship analysis, and biological activity

HIV-1 integrase, which catalyzes the integration of the viral genome into the cellular chromosome, is an essential enzyme for retroviral replication, and represents an attractive and validated target in the development of therapeutics against AIDS. In this paper, 17 amide-containing novel diketoacids were designed and synthesized, and their ability to inhibit HIV-1 integrase was tested. The structure-activity relationships were also analyzed.

Novel short-step synthesis of functionalized γ-phenyl-β- hydroxybutenoates and their cyclization to 4-hydroxycoumarins via the N-hydroxybenzotriazole methodology

A novel method for the synthesis of functionalized 3-substituted 4-hydroxycoumarins is reported. C-Acylation compounds were derived from the reaction of the N-hydroxybenzotriazole ester of the functionalized acetyl salicylic acids and a variety of active methylene compounds and cyclized to the title compounds. The synthesis is simple and the compounds are produced in yields varying from 39 to 80%. The structure of the newly prepared C-acylation compounds was thoroughly studied through NMR spectroscopy for the first time in the literature.

Drug evolution concept in drug design: 1. Hybridization method

A novel concept, "drug evolution", is proposed to develop chemical libraries that have a high probability of finding drugs or drug candidates. It converts biological evolution into chemical evolution. In this paper, we present "hybridization" drug evolution, which is the equivalent of sexual recombination of parental genomes in biological evolution. The hybridization essentially shuffles the building blocks of the parent drugs and ought to drug(s); no drug evolution can otherwise occur. We hybridized two drugs, benzocaine and metoclopramide and generated 16 molecules that include the parent drugs, four known drugs, and two molecules whose therapeutic activities are reported. The unusually high number of drugs and drug candidates in the library encourages high expectations of finding new drug(s) or drug candidate(s) within the remaining eight compounds. Interestingly, the therapeutic applications of the eight drugs or drug candidates in the library are fairly diverse as 38 therapeutic applications and 25 molecular targets are counted. Therefore, the library fits as a general chemical library for unspecified therapeutic activities. The hybridization of other two drugs, aspirin and cresotamide, is also described to demonstrate the generality of the method.

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.

A highly practical route to 2-methylchromones from 2-acetoxybenzoic acids

2-Methylchromones were accessed via a keto ester condensation on 2-acetoxybenzoyl chloride, followed by cyclization and decarboxylation. No column chromatography was required in the process.

Synthesis and biological evaluation of CX-659S and its related compounds for their inhibitory effects on the delayed-type hypersensitivity reaction

In order to find novel nonsteroidal compounds possessing an inhibitory activity against delayed-type hypersensitivity (DTH) reactions, we conducted random screening using a picryl chloride (PC)-induced contact hypersensitivity reaction (CHR) in mice, and found compound 1 as a lead compound. Then we synthesized and evaluated an extensive series of 5-carboxamidouracil derivatives focused on both the uracil and the antioxidative moieties. Among them, we found that the hindered phenol moiety was necessary to exhibit the activities; especially, compounds 28a-28c having the partial structure of vitamin E were found to exert potent activities against the DTH reaction by both oral and topical administration. And compound 28c showed antioxidative activity against lipid peroxidation with an IC50 of 5.9μM. Compound 28c (CX-659S) was chosen as a candidate drug for the treatment of cutaneous disorders such as atopic dermatitis and allergic contact dermatitis. Copyright (C) 2000 Elsevier Science Ltd.